Holen Sie sich die Stockscreener-App
2.02
1.94%
-0.04
Handel nachbörslich:
2.02
Schlusskurs vom Vortag:
$2.06
Offen:
$2.03
24-Stunden-Volumen:
604.89K
Relative Volume:
0.75
Marktkapitalisierung:
$162.75M
Einnahmen:
$52.74M
Nettoeinkommen (Verlust:
$-6.60M
KGV:
-23.91
EPS:
-0.0845
Netto-Cashflow:
$-13.63M
1W Leistung:
+2.54%
1M Leistung:
+2.02%
6M Leistung:
+14.77%
1J Leistung:
+47.45%
1-Tages-Spanne:
$2.00
$2.08
1-Wochen-Bereich:
$1.9701
$2.135
52-Wochen-Spanne:
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.02 | 165.98M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
PLX Q1 2026 Earnings: EPS Rockets Past Estimates, Stock Edges LowerGuidance vs Actual - newsline.com
Protalix BioTherapeutics (PLX) Holds Near Key Support After Mild DeclineZero Lag EMA - newsline.com
Protalix BioTherapeutics (PLX) Holds Near Support After Modest DeclinePut Dominated - thelegaladvocate.com
Protalix BioTherapeutics (PLX) Consolidates Near Support After Mild DeclineCombination Correction - newsline.com
H.C. Wainwright Maintains Protalix Biotherapeutics(PLX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Protalix BioTherapeutics (PLX) Rises 1.43% as Biotech Stock Tests Key ResistancePrice Gap Fill - The Legal Advocate
3 Penny Stocks With Market Caps Larger Than $100M To Consider - Sahm
PLX Q1 2026 Earnings: Massive EPS Surprise as Protalix BioTherapeutics Reports Strong ProfitabilityRevenue Growth Outlook - The Legal Advocate
PLX Stock Price, Quote & Chart | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Protalix Highlights Elfabrio Dosing Approvals and Growth Plans - TipRanks
Protalix BioTherapeutics Advances Rare Disease Treatments with Elfabrio® and PRX-115, Achieves Key Regulatory and Pipeline Milestones - Minichart
Protalix BioTherapeutics (PLX) posts new May 2026 corporate presentation for investors - Stock Titan
Protalix BioTherapeutics appoints Gilad Mamlok as CFO - MSN
Protalix BioTherapeutics (PLX) Q1 2026 8-K: EPS Not Disclosed, R - GuruFocus
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone - MSN
Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets - The Globe and Mail
PLX: Chiesi milestone received - MSN
PLX: Chiesi Milestone Received - Yahoo Finance
Protalix BioTherapeutics 1Q Rev $33.8M >PLX - Moomoo
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results - Sahm
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics, Inc. Q1 2026 Financial Results & SEC 10-Q Filing Overview - Minichart
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlig - GuruFocus
Protalix BioTherapeutics Delivers 234% Revenue Growth in Q1 2026 - AlphaStreet
Protalix BioTherapeutics Releases Q1 2026 Financial Results - AlphaStreet
Protalix BioTherapeutics Reports Q1 2026 Results: $18.3M Net Income, $25M Milestone From Chiesi, and Strong Guidance for 2026 - Minichart
Protalix BioTherapeutics Backs 2026 Rev $78M-$83M >PLX - Moomoo
Protalix BioTherapeutics (PLX) Reports Q1 Earnings with Strong R - GuruFocus
Earnings call transcript: Protalix Q1 2026: Earnings beat expectations, stock rises By Investing.com - Investing.com South Africa
PLX: $25M milestone drives strong Q1, with 2026 guidance reaffirmed and pipeline advancing - TradingView
Earnings call transcript: Protalix Q1 2026: Earnings beat expectations, stock rises - Investing.com
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call - Yahoo Finance
Protalix BioTherapeutics 1Q 2026: Revenue $33.75M, Net income $18.32M, EPS $0.22— 10-Q Summary - TradingView
Protalix Hits Profitability, Fuels Pipeline with Elfabrio Milestone - BriefGlance
Protalix (PLX) turns Q1 2026 profit as Elfabrio EU milestone boosts cash - Stock Titan
Protalix reports Q1 2026 net income $18.3M on $33.8M revenue, $25M Chiesi milestone - TradingView
Protalix: Q1 Earnings Snapshot - marketscreener.com
BRIEF-Protalix BioTherapeutics Q1 EPS USD 0.23 - TradingView
Press Release: Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results - Moomoo
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 - Barchart.com
Protalix BioTherapeutics Q1 earnings preview - MSN
Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors? - MSN
Earnings Preview: PLX to Report Financial Results Pre-market on May 13 - Moomoo
Protalix to discuss quarterly results and business update May 13 - Stock Titan
MSN Money - MSN
Protalix BioTherapeutics (PLX) sets 2026 director, pay and stock plan votes - Stock Titan
[ARS] Protalix BioTherapeutics, Inc. SEC Filing - Stock Titan
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
Protalix CFO updates Form 3 share and option holdings | PLX Insider Trading - Stock Titan
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):